News Outlets Continue to Report Avandia’s Declining Sales, Status

October 27th, 2008 | Category: General Health

The write-up found that by 2011 Avandia, a type 2 diabetes non-insulin treatment, will see a decrease in sales considering of the continued cloud of controversy shrouding the drug’s effects and linking the drug to early onset osteoporosis and increased risk of heart failure among patients. An October 10, 2008 essay

from Market Watch, a part of The Wall Street Journal’s digital network, published an anti-diabetics market forecast, which found that Avandia and Actos are and will continue to lose market shares and their leading marketing positions status considering of unresolved safety concerns.

Original post by articles@legalview.com (Katie Kelley)

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
Related Articles
  • Avandia Makers Issue New Warning as Net Sales Plummet
  • Manufacturers of Type 2 Diabetes Prescription Drug Receive FDA Warning For Failure to Report Avandia
  • Study Finds Avandia Safety Risks Higher Than Peer Drugs Including Actos
  • A Group of Doctors Petition FDA For Vegan Label on Avandia
  • Diabetes Drug Avandia Associated with Increased Risk of Osteoporosis

    • No comments yet. Be the first.

    Leave a reply